What is Parse Biosciences?
Headquartered in Seattle, Parse Biosciences is a global life sciences innovator dedicated to developing scalable and accessible single-cell sequencing solutions. At the core of its product suite is the pioneering Evercode platform, which enables researchers to conduct complex transcriptomic and immune profiling without the requirement for specialized, high-cost instrumentation. By removing these technical barriers, the company empowers laboratories to accelerate breakthroughs in critical fields such as cancer treatment, stem cell therapy, and immunology. Its market position is defined by a commitment to making advanced biological analysis more accessible, thereby fostering a more inclusive and efficient ecosystem for scientific discovery.
How much funding has Parse Biosciences raised?
Parse Biosciences has raised a total of $98.5M across 3 funding rounds:
Other Financing Round
$7M
Series B
$41.5M
Series C
$50M
Other Financing Round (2021): $7M with participation from Bioeconomy Capital
Series B (2022): $41.5M led by Logos Capital, Marshall Wace, Janus Henderson Investors, Soleus Capital, and Bioeconomy Capital
Series C (2023): $50M supported by Sahsen Ventures, Bioeconomy Capital, Marshall Wace, Janus Henderson Investors, Soleus Capital, and Saras Capital
Key Investors in Parse Biosciences
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy.
Marshall Wace
Marshall Wace LLP is a global alternative investment manager specializing in long/short equity, providing significant institutional backing to high-growth sectors.
Soleus Capital
Soleus Capital is a healthcare investment firm that specializes in innovative life sciences sectors, including biotech, medtech, diagnostics, and genomics.
What's next for Parse Biosciences?
With the successful completion of its latest financing round, Parse Biosciences is poised to enter a new phase of operational scaling and market penetration. The strategic deployment of this capital will likely focus on the global expansion of its Evercode platform, further diversifying its application in clinical and academic settings. As the company continues to partner with labs and organizations worldwide, the focus will shift toward sustaining long-term growth through the continuous refinement of its sequencing tools. By maintaining its trajectory of innovation, Parse Biosciences is set to remain at the forefront of the genomics revolution, providing the essential infrastructure required for the next generation of biomedical advancements.
See full Parse Biosciences company page
